SCHEMBL26320537

SCHEMBL26320537

Cc1ccc(C(=O)C[S+]([O-])c2nc3ccccc3s2)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.47
ALPG P10696 4/20 0.47
GCGR P47871 1/20 0.47
HSD17B1 P14061 3/20 0.43
HSD17B2 P37059 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2B6 P20813 1/20 0.43
TOP1 P11387 2/20 0.41
PTPN1 P18031 1/20 0.39
MAPT P10636 8/20 0.38
KDM4E B2RXH2 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23196655 0.90 ALPG (0.58) ALPLALPGGCGRHSD17B1HSD17B2
SCHEMBL26320532 0.78 RAB9A (0.40) MAPTKDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL25759375 0.77 MAPT (0.50) CYP1A2CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL11429532 0.75 SMN1; SMN2 (0.48) CYP1A2CYP2C9CYP2C19MAPTSMN1; SMN2
SCHEMBL26320568 0.75 ALPL (0.80) ALPLALPGGCGRCYP1A2CYP3A4
SCHEMBL26320536 0.74 ALPL (0.47) ALPLALPGGCGRHSD17B1HSD17B2
SCHEMBL26320518 0.71 HSD17B1 (0.38) ALPLALPGHSD17B1HSD17B2CYP1A2
SCHEMBL20875226 0.71 PAX8 (0.44) CYP1A2CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL19403461 0.71 PAX8 (0.44) CYP1A2CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL11499868 0.70 SMN1; SMN2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293499-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO US GOV VETERANS AFFAIRS (US) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293499-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO NFKBIA, NCBP1, NFKB1 ALPL 4374/4885ALPG 4545/4885GCGR 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.